Recurrent Imatinib Resistant Gastrointestinal Stromal Tumour of The Rectum: A Case Report
Abstract
Gastrointestinal stromal tumors (GISTs) are rare neoplasms of the GIT with an incidence of about 0.1-3% of all GI malignancies. They are thought to arise from the interstitial cells of Cajal. Expression of the c-kit gene protein product, CD117 is an important defining feature of GISTs. The most common GIST sites are the stomach (50%-70%) followed by the small intestine (25%-35%), whereas only about 5%-10% of all GISTs start in the rectum. Rectal GISTs make up 0.1% of all tumors originating in the rectum. In this report, we describe a case of imatinib resistant rectal GIST in a 65 year old woman which recurred following primary resection and was treated by debulking surgery and followed by Sunitinib chemotherapy.
Full Text:
PDFReferences
Maingot's Abdominal Operations, 12th Edition. 1st ed. McGraw-Hill Professional; 2012.
Vivek Vasudeo, Upendra Kumar, Shital Malua, Bikash Kumar. Rectal gastrointestinal stromal tumor: a case report. International Journal of Contemporary Medical Research 2016;3(5): 1322-1324.
Hamada M, Ozaki K, Horimi T, Tsuji A, Nasu Y, Iwata J et al. Recurrent rectal GIST resected successfully after preoperative chemotherapy with imatinib mesylate. International Journal of Clinical Oncology. 2008;13(4):355-360.
Grassi N. Gastrointestinal stromal tumour of the rectum: Report of a case and review of literature. World Journal of Gastroenterology. 2008;14 (8):1302.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
An Initiative of The Tamil Nadu Dr MGR Medical University